These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26795674)

  • 1. Deconstructing the measure of vaccine efficacy against disease irrespective of HPV in HPV vaccine clinical trials.
    Bautista OM; Luxembourg A
    Contemp Clin Trials; 2016 Mar; 47():254-8. PubMed ID: 26795674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
    Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
    N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From the monovalent to the nine-valent HPV vaccine.
    Pils S; Joura EA
    Clin Microbiol Infect; 2015 Sep; 21(9):827-33. PubMed ID: 25980355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and incidence of HPV genital infection in women.
    Velicer C; Zhu X; Vuocolo S; Liaw KL; Saah A
    Sex Transm Dis; 2009 Nov; 36(11):696-703. PubMed ID: 19652630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introducing human papillomavirus vaccines - questions remain.
    Paavonen J; Lehtinen M
    Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review.
    Maver PJ; Poljak M
    Vaccine; 2018 Aug; 36(36):5416-5423. PubMed ID: 28801154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
    Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
    Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Human papillomavirus vaccine. Efficacy and safety].
    Bruni L; Serrano B; Bosch X; Castellsagué X
    Enferm Infecc Microbiol Clin; 2015 May; 33(5):342-54. PubMed ID: 25937455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.
    Pitisuttithum P; Velicer C; Luxembourg A
    Expert Rev Vaccines; 2015; 14(11):1405-19. PubMed ID: 26366475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.
    Skinner SR; Apter D; De Carvalho N; Harper DM; Konno R; Paavonen J; Romanowski B; Roteli-Martins C; Burlet N; Mihalyi A; Struyf F
    Expert Rev Vaccines; 2016; 15(3):367-87. PubMed ID: 26902666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic human papillomavirus vaccines: past, present and future.
    Anderson LA
    Pathology; 2012 Jan; 44(1):1-6. PubMed ID: 22157686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.
    Luxembourg A; Bautista O; Moeller E; Ritter M; Chen J
    Contemp Clin Trials; 2015 May; 42():18-25. PubMed ID: 25749310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research progress regarding the clinical evaluation on recombinant human papillomavirus vaccines].
    He WG; Zhao J; Huang SJ; Wu T
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Jun; 37(6):904-8. PubMed ID: 27346126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
    ; Romanowski B; de Borba PC; Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; Aoki F; Ramjattan B; Shier RM; Somani R; Barbier S; Blatter MM; Chambers C; Ferris D; Gall SA; Guerra FA; Harper DM; Hedrick JA; Henry DC; Korn AP; Kroll R; Moscicki AB; Rosenfeld WD; Sullivan BJ; Thoming CS; Tyring SK; Wheeler CM; Dubin G; Schuind A; Zahaf T; Greenacre M; Sgriobhadair A
    Lancet; 2009 Dec; 374(9706):1975-85. PubMed ID: 19962185
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.